What happens when SEND escapes Toxicology?
Marc Ellison
If we want AI to help us search, analyze and identify patterns in scientific data, giving it consistently structured data seems like a pretty good starting point.
SEND Blog
Application Areas
Clinical Stage
Product
Webinar Recap: SEND v4.0 Readiness Starts at Data Collection
Instem Team
This webinar indicated
how SEND v4.0 readiness transcends simply translating existing data differently. In some cases, organizations will need to reconsider what information is captured and how it is captured.
Webinar Recap: When SEND Quality Matters Most
Instem Team
Our recent webinar, “When SEND Quality Matters Most”, explored the recent FDA communications regarding data quality, why regulatory expectations are shifting, where common issues arise, and how organizations can strengthen confidence before filing SEND datasets...
Instem Interact 2026 – A Resounding Success
Instem Team
Turning Insight into Innovation in Preclinical R&D
What the FDA Webcast Revealed About SEND (and Why It Matters)
Marc Ellison
“For the first time, the FDA openly acknowledged that they are rejecting some SEND datasets because the quality isn’t good enough. No ambiguity. Just a clear statement that quality matters, and that poor SEND has...
White Paper: Preparing Your Team for SEND 4.0
Instem Team
SEND 4.0 introduces one of the most significant updates to nonclinical data standards, expanding scientific coverage and modernizing core structures across the SEND ecosystem. This white paper outlines the key changes such as new domains,...
Stay up to Date
Get expert tips, industry news, and fresh content delivered to your inbox.
